6.44 USD
▲-0.17+4.55%
盘后 6.29 +2.03%
2026-08-03
市值
$2.24B
市盈率
—
EPS
-0.42
股息率
—
52 周区间
2.18 – 9.75
成交量
4.65M
Beta
1.52
目标价
12.78
52W 低 2.1852W 高 9.75
价格走势
公司简介
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on developing product candidates for cancer treatment. The company’s lead product candidate is IBTROZI (taletrectinib), a ROS1 inhibitor for the treatment of patients with ROS1+ non-small cell lung cancer. It is also developing Safusidenib, an inhibitor of mutant isocitrate dehydrogenase 1 in phase 3 clinical trials for the maintenance treatment of high-risk or high-grade IDH1-mutant astrocytoma with safusidenib against placebo. The company was founded in 2018 and is headqua...